Genmab Grants Stock Units and Warrants to Employees

Genmab ( (GMAB) ) just unveiled an announcement.

On September 26, 2025, Genmab A/S announced the grant of 14,353 restricted stock units and 9,681 warrants to its employees and subsidiaries. These awards are part of Genmab’s strategy to incentivize its workforce, with restricted stock units and warrants vesting over three years. The initiative underscores Genmab’s commitment to employee engagement and aligns with its long-term growth and innovation goals in the biotechnology sector.

The most recent analyst rating on (GMAB) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, focusing on innovative and differentiated antibody therapeutics. Established in 1999, the company aims to improve the lives of patients with cancer and other serious diseases through advanced antibody technology platforms. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators, with a vision to transform patient lives by 2030.

Average Trading Volume: 1,268,985

Technical Sentiment Signal: Buy

Current Market Cap: $17.96B

For an in-depth examination of GMAB stock, go to TipRanks’ Overview page.